PURPOSE: To examine the antagonistic effects of anti-extracellular matrix metalloprotease inducer (anti-EMMPRIN) antibody when combined with chemotherapy using a hypovascular pancreatic tumor model. PROCEDURES: Severely compromised immunodeficient mice bearing orthotopic MIA PaCa-2 tumors were used (five to six animals per group). Dynamic contrast-enhanced magnetic resonance imaging was used to examine the relationship between tumor vascularity and size. Therapy was initiated when tumors were hypovascular. Treatments included: (1) gemcitabine alone, (2) anti-EMMPRIN antibody alone, and (3) combination, each for 2 weeks. Additionally, another treatment arm included β-lapachone, an NAD(P)H/quinone 1 (NQO1) bioactivated agent. (18)F-fluoro-D-glucose-positron emission tomography/computed tomography imaging was used weekly to monitor therapeutic effects. RESULTS: Gemcitabine or anti-EMMPRIN monotherapy significantly delayed tumor growth, but the combination therapy showed an antagonistic effect. Similarly, tumor growth was significantly suppressed by β-lapachone alone, and additive effects were noted when combined with gemcitabine, but the therapeutic efficacy was reduced when anti-EMMPRIN antibody was added. CONCLUSIONS: Anti-EMMPRIN antibody with chemotherapy in hypovascular tumors results in antagonistic effects.
PURPOSE: To examine the antagonistic effects of anti-extracellular matrix metalloprotease inducer (anti-EMMPRIN) antibody when combined with chemotherapy using a hypovascular pancreatic tumor model. PROCEDURES: Severely compromised immunodeficientmice bearing orthotopic MIA PaCa-2 tumors were used (five to six animals per group). Dynamic contrast-enhanced magnetic resonance imaging was used to examine the relationship between tumor vascularity and size. Therapy was initiated when tumors were hypovascular. Treatments included: (1) gemcitabine alone, (2) anti-EMMPRIN antibody alone, and (3) combination, each for 2 weeks. Additionally, another treatment arm included β-lapachone, an NAD(P)H/quinone 1 (NQO1) bioactivated agent. (18)F-fluoro-D-glucose-positron emission tomography/computed tomography imaging was used weekly to monitor therapeutic effects. RESULTS:Gemcitabine or anti-EMMPRIN monotherapy significantly delayed tumor growth, but the combination therapy showed an antagonistic effect. Similarly, tumor growth was significantly suppressed by β-lapachone alone, and additive effects were noted when combined with gemcitabine, but the therapeutic efficacy was reduced when anti-EMMPRIN antibody was added. CONCLUSIONS: Anti-EMMPRIN antibody with chemotherapy in hypovascular tumors results in antagonistic effects.
Authors: Tobias Heye; Matthew S Davenport; Jeffrey J Horvath; Sebastian Feuerlein; Steven R Breault; Mustafa R Bashir; Elmar M Merkle; Daniel T Boll Journal: Radiology Date: 2012-12-06 Impact factor: 11.105
Authors: V Ellenrieder; B Alber; U Lacher; S F Hendler; A Menke; W Boeck; M Wagner; M Wilda; H Friess; M Büchler; G Adler; T M Gress Journal: Int J Cancer Date: 2000-01-01 Impact factor: 7.396
Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: A G Braundmeier; A T Fazleabas; B A Lessey; H Guo; B P Toole; R A Nowak Journal: J Clin Endocrinol Metab Date: 2006-03-07 Impact factor: 5.958
Authors: Melissa S Bentle; Kathryn E Reinicke; Erik A Bey; Douglas R Spitz; David A Boothman Journal: J Biol Chem Date: 2006-08-17 Impact factor: 5.486
Authors: Xiumei Huang; Ying Dong; Erik A Bey; Jessica A Kilgore; Joseph S Bair; Long-Shan Li; Malina Patel; Elizabeth I Parkinson; Yiguang Wang; Noelle S Williams; Jinming Gao; Paul J Hergenrother; David A Boothman Journal: Cancer Res Date: 2012-04-24 Impact factor: 13.312
Authors: Erik A Bey; Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Chin-Rang Yang; Luc Girard; John D Minna; William G Bornmann; Jinming Gao; David A Boothman Journal: Proc Natl Acad Sci U S A Date: 2007-07-03 Impact factor: 12.779
Authors: Hyunki Kim; Sharon Samuel; John W Totenhagen; Marie Warren; Jeffrey C Sellers; Donald J Buchsbaum Journal: J Vis Exp Date: 2015-04-18 Impact factor: 1.355
Authors: Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui Journal: Antioxid Redox Signal Date: 2017-12-20 Impact factor: 8.401
Authors: Muhammad Shaalan Beg; Xiumei Huang; Molly A Silvers; David E Gerber; Joyce Bolluyt; Venetia Sarode; Farjana Fattah; Ralph J Deberardinis; Matthew E Merritt; Xian-Jin Xie; Richard Leff; Daniel Laheru; David A Boothman Journal: J Surg Oncol Date: 2017-03-27 Impact factor: 2.885